TOPIC: AbbVie's Mavyret Approved

Official price for eight weeks is set at US$26,400.

Mavyret is a combo of an NS3/4a inhibitor, Glecaprevir, and an NS5A inhibitor, Pibrentasvir.

Seattle Times: www.seattletimes.com/business/fda-oks-ne...orms-of-hepatitis-c/
Fierce Pharma: www.fiercepharma.com/pharma/abbvie-s-new...ndercuts-competition
ABC: abcnews.go.com/Health/wireStory/fda-oks-...s-hepatitis-49019076

Further on this, AbbVie have also announced approval for treatment of all genotypes in Japan has been granted.

news.abbvie.com/news/press-releases/abbv...s-gt1-6-in-japan.htm